ResMed Inc. 10-Q Summary: Quarter Ended September 30, 1997
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 1997. ResMed Inc. is a Delaware holding company for ResCare Holdings Ltd., an Australian entity that designs, manufactures, and markets devices for the evaluation and treatment of sleep-disordered breathing, primarily obstructive sleep apnea. Principal manufacturing is located in Australia, with major distribution and sales sites in the United States, United Kingdom, and Europe.
Key Financial Metrics
| Metric (in thousands) | Q1 1997 | Q1 1996 |
|---|---|---|
| Net Revenues | $13,978 | $11,141 |
| Gross Profit | $8,553 | $6,291 |
| Gross Margin | 61.2% | 56.5% |
| Operating Income | $2,638 | $1,578 |
| Net Income | $2,157 | $1,840 |
| Diluted EPS | $0.29 | $0.25 |
| Cash from Operations | $1,516 | $1,783 |
| Cash & Equivalents (End of Period) | $13,422 | $6,455 |
| Total Debt (Current + Long-term) | $532 | $548 |
Note: Debt figures represent the outstanding principal balance of the Australian Federal Government loan ($532k at Sept 30, 1997). Total current liabilities were $9,490k.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 25% to $14.0 million, driven by higher unit sales of flow generators and accessories in North America and Europe. North American revenue rose to $7.0 million from $4.4 million.
- Margin Expansion: Gross margin improved to 61% from 56%, attributed to a shift to higher-margin products and a weaker Australian dollar reducing manufacturing costs.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 19% due to increased personnel (from 88 to 119). Research and development (R&D) expenses surged 60% to $1.3 million due to consulting fees for new product development.
- Other Income Decline: Net other income dropped 42% to $656k, primarily due to a reduction in foreign exchange gains ($332k vs. $750k in the prior year), partially offset by increased government grants.
- Tax Rate: The effective tax rate increased to approximately 35% from 32%, reflecting changes in Australian R&D tax concessions.
Outlook, Risks, and Contingencies
- Liquidity: The company maintains strong liquidity with approximately $28 million in cash and marketable securities. Working capital increased to $36 million.
- Capital Expenditures: Capital spending was $1.6 million, primarily for the construction of a new Australian facility, software, and production tooling.
- Legal Proceedings: Significant patent litigation is ongoing against competitor Respironics in the U.S. regarding alleged infringement of four patents. Additionally, Respironics and its Australian distributor have filed a claim in Australia alleging unfair trade practices, seeking approximately $730,000 in damages. Management intends to defend these actions but notes uncertainty regarding outcomes and potential costs.
- Foreign Exchange Risk: The company remains exposed to currency fluctuations, particularly the Australian dollar, though it utilizes foreign currency option contracts to hedge anticipated cash flows.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing patent litigation with Respironics in both the U.S. and Australia.
- Monitor the progress of the new Australian manufacturing facility construction and its impact on future capacity and costs.
- Assess the sustainability of the 61% gross margin given the volatility of the Australian dollar and competitive pricing pressures.
- Review the trajectory of R&D spending to ensure new product development aligns with revenue growth targets.
- Confirm the terms and repayment schedule of the Australian Federal Government loan ($532k outstanding).